These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6652028)

  • 1. High-dose cytosine arabinoside (Ara-C) in colorectal cancer.
    Kanojia M; Kantarjian H; Ajani J; Barlogie B
    Br J Cancer; 1983 Dec; 48(6):869-71. PubMed ID: 6652028
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of cytosine arabinoside in advanced large bowel cancer.
    Cullinan SA; O'Connell MJ; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ; Frytak S; Rubin J
    Cancer Treat Rep; 1977 Dec; 61(9):1725-6. PubMed ID: 340037
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
    Davis S; Park YK
    Cancer Treat Rep; 1978 Oct; 62(10):1557-9. PubMed ID: 709556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
    Hansen RM; Banerjee TK; Davis HL; Zaentz SD; Schiferl EA; Ousley JL; Pogodzinski AE; Trump DL
    Wis Med J; 1988 May; 87(5):20-3. PubMed ID: 3291405
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of cyclophosphamide and cytarabine in the treatment of metastatic adenocarcinoma of the colon and rectum.
    Denefrio JM; Kaplan RS; Eisenberger MA; Lessner HE
    Cancer Treat Rep; 1981; 65(1-2):163-4. PubMed ID: 7226166
    [No Abstract]   [Full Text] [Related]  

  • 6. Peroral therapy with cytosine arabinoside. Preliminary laboratory and clinical findings.
    Goldenberg DM; Schricker KT; von der Emde J; Sögtrop HH
    Arzneimittelforschung; 1968 Jun; 18(6):712-4. PubMed ID: 5755808
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
    Gailani S; Holland JF; Falkson G; Leone L; Burningham R; Larsen V
    Cancer; 1972 May; 29(5):1308-13. PubMed ID: 4623252
    [No Abstract]   [Full Text] [Related]  

  • 8. A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).
    Burke PJ; Owens AH; Colsky J; Shnider BI; Edmonson JH; Schilling A; Brodovsky HS; Wallace HJ; Hall TC
    Cancer Res; 1970 May; 30(5):1512-5. PubMed ID: 5426952
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer.
    O'Connell MJ; Rubin J; Hahn RG; Kvols LK; Moertel CG
    Cancer Treat Rep; 1987 Mar; 71(3):333-4. PubMed ID: 3815402
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of mitoxantrone in advanced colorectal cancer.
    Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
    Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
    Rougier P; Droz JP; Ducreux M; Kac J; Spielmann M; Crespon B; Ley G; Zimmermann P; Theodore C; Chavy A
    Bull Cancer; 1983; 70(5):434-6. PubMed ID: 6607759
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
    Schutt AJ; Hahn RG; Moertel CG; O'Connell MJ; Rubin J; Creagan ET
    Cancer Treat Rep; 1983 May; 67(5):505-6. PubMed ID: 6406062
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of hycanthone in patients with advanced colorectal carcinoma.
    Schutt AJ; Dalton RJ; Kovach JS; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1983 Jun; 67(6):593-4. PubMed ID: 6861166
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of cytembena (NSC-104801) in advanced colorectal carcinoma.
    Moertel CG; Schutt AJ; Hahn RG; Marciniak TA; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(3):581-3. PubMed ID: 1243107
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
    Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
    Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial of maytansine in patients with advanced colorectal carcinoma.
    O'Connell MJ; Shani A; Rubin J; Moertel CG
    Cancer Treat Rep; 1978 Aug; 62(8):1237-8. PubMed ID: 356981
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of vindesine in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1979; 63(11-12):2097-8. PubMed ID: 526944
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial.
    Locker GY; Lanzotti V; Sweet D; Lad T; Khandekar J; Stiff P; Johnson C; Miller S
    Cancer Treat Rep; 1984 Oct; 68(10):1303-4. PubMed ID: 6525605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.